About

Michael David is a Professor in the Department of Biology at the University of California, San Diego (UCSD), a position he has held since 2008. He has been a member of the UCSD Cancer Center since 1998. His academic background includes a Pharm.D. and a Ph.D. in Pharmacology from the University of Vienna, Austria, completed in 1989 and 1991 respectively. Following his doctoral studies, he conducted postdoctoral research at the Center for Biologics Evaluation and Research from 1991 to 1996. He joined UCSD Biology as an Assistant Professor in 1996, was promoted to Associate Professor in 2002, and then to full Professor in 2008. Throughout his career, he has received several honors including the Schroedinger Award from the Austrian Science Foundation, the Fogarty Fellowship from the NIH, and Scholar Awards from the Sidney Kimmel Foundation for Cancer Research and the National Multiple Sclerosis Society. He also serves on the editorial board of the Journal of Biological Chemistry since 2002. Professor David's research focuses on the biology of interferons, a family of polypeptides known for their diverse biological effects such as inhibition of cell growth, protection against viral infections, and modulation of immune responses. These pleiotropic effects have led to the widespread clinical use of interferons in treating cancers, viral infections, and autoimmune diseases. His laboratory aims to elucidate the molecular mechanisms by which interferons achieve these diverse biological functions. Additionally, his research explores the innate immune processes that regulate the induction of interferon production following pathogen recognition, contributing to a deeper understanding of immune system function and response.

Research topics

• Sociology
• Nursing
• Family medicine
• Medical emergency
• Medicine
• Medical education

Selected publications

• Pearls & Oy-sters: Bilateral globus pallidus lesions in a patient with COVID-19

  Neurology · 2020 · 23 citations

  • Sociology
  • Medicine
  • Medical education

  Neurologic complications are occurring in coronavirus disease 2019 (COVID-19), and these patients should be monitored for neurologic symptoms.c When evaluating abnormal imaging findings in patients with COVID-19, the presence and specific pattern of deep gray structure involvement can be an important clue to etiology. Oy-sters cBrain imaging should be considered in the context of patients with COVID-19 with neurologic symptoms, even in the absence of focal findings on neurologic examination.c Given the dissociation between degree of hypoxemia and clinical symptoms that can be seen in patients with COVID-19, it is possible that unusual presentations of hypoxicischemic brain injury may emerge.COVID-19, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was originally described as a viral infection primarily affecting the respiratory tract.Neurologic complications are emerging, and have been reported in 36% of patients hospitalized with COVID-19 and in 46% of those with severe respiratory involvement. 1 The most common neurologic manifestations reported are dizziness, headache, impaired consciousness, dysgeusia, and hyposmia.An increased risk of stroke has also been identified.We report the case of a 52-year-old woman with bilateral globus pallidus lesions in the setting of COVID-19.The patient had a history of hypertension and newly diagnosed, poorly controlled type II diabetes mellitus (hemoglobin A1c of 17.4).She developed bilateral hand paresthesias the week prior to presentation, followed by dyspnea, cough, headache, and confusion.She presented to the emergency department and was afebrile, but tachycardic (115 beats per minute), hypertensive (220/118 mm Hg), and hypoxemic (oxygen saturation 49% on room air).She was alert and conversant, with no focal neurologic deficits.She had refractory hypoxemia despite 20 L/min supplemental oxygen.She was intubated and placed on mechanical ventilation for hypoxemic respiratory failure within 1 hour of presentation.SARS-CoV-2 was detected by rapid, real-time reverse-transcriptase polymerase chain reaction on the Cepheid GeneXpert system from a nasopharyngeal swab sample.Chest CT scan showed extensive bilateral, patchy, peripheral-predominant ground glass opacities with consolidation.Head CT demonstrated symmetric hypoattenuation in the bilateral globi pallidi with surrounding small foci of hyperattenuation (figure, A).Carboxyhemoglobin was not elevated and urine toxicology screen was negative.

  PublisherOA PDFDOI

Recent grants

• Genomics of S. Aureus Colonization after Initial and Recurrent Skin Infections and the Impact of Antibiotics

  NIH · $3.8M · 2018–2025

• NIH Grant K23AI095361

  NIH · $633k · 2016

Frequent coauthors

• Robert S. Daum

  University of Chicago

  57 shared

• Susan Boyle‐Vavra

  University of Chicago

  36 shared

• Loren G. Miller

  21 shared

• Ethan Morgan

  The Ohio State University

  17 shared

• Timothy D. Read

  Emory University

  17 shared

• Samantha J. Eells

  UCLA Medical Center

  17 shared

• Ebbing Lautenbach

  17 shared

• David A. Pegues

  University of Pennsylvania

  16 shared

Education

• Clinical Fellow, Infectious Diseases, Medicine

  University of Chicago Medical Center

  2009

• PhD, History

  University of Chicago

  2007

• MS, Health Studies

  University of Chicago

  2007

• Research Fellow, Robert Wood Johnson Clinical Scholars Program

  University of Chicago

  2006

• Categorical Internal Medicine Residency, Medicine

  Yale-New Haven Hospital

  2004

• MD, School of Medicine

  Yale University

  2001

• BA, Russian Language and Literature

  Amherst College

  1992

Similar researchers at University of California, San Diego

• Ronald M. Evansh-300
• Rob Knighth-297
• Michael (Geoff) Rosenfeldh-224
• Don W. Clevelandh-213
• Anders M Daleh-209